Personalized DNA Vaccine for Glioblastoma
Trial Summary
What is the purpose of this trial?
This trial is testing a custom-made vaccine designed to help the immune system attack brain cancer cells. It targets patients with a specific type of brain cancer that hasn't responded to usual treatments. The vaccine works by teaching the immune system to recognize and destroy cancer cells based on unique markers.
Research Team
Tanner M Johanns, M.D., Ph.D.
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
This trial is for adults with newly diagnosed, unmethylated glioblastoma who've had a craniotomy or resection. Participants must consent to genome sequencing and agree to use contraception. They should have normal organ function, not be on high-dose steroids, and can't have other cancers within the last 3 years or any immune system disorders.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Standard radiation therapy administered per standard of care
Treatment
Participants receive GNOS-PV01 + INO-9012 on Days 1, 22, and 43 of Cycle 1 and then on Day 1 of each subsequent cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Personalized neoantigen DNA vaccine
Personalized neoantigen DNA vaccine is already approved in United States for the following indications:
- Pediatric recurrent brain tumors
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Geneos Therapeutics
Industry Sponsor
The Foundation for Barnes-Jewish Hospital
Collaborator